Search - tctmd.com

Displaying 581 - 600 of 696

Sort: Relevancy | Date

News Daily News

Repositionable Valve Yields Promising 2-Year TAVR Results

December 06, 2011

News Daily News

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

December 04, 2011

News Conference News

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

November 27, 2011

News Industry News

Boston Scientific Receives FDA Approval for PROMUS Element™ Plus Platinum Chromium Stent System

November 21, 2011

News Conference News

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

November 17, 2011

News Conference News

PRISM Individualized Informed Consent Improves PCI Choice, Experience

November 14, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Conference News

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

November 13, 2011

News Conference News

Two New SES Show Improvement Over First-Generation Stents

Yael L. Maxwell

November 10, 2011

News Industry News

Paclitaxel-coated balloon angioplasty demonstrates superior results

November 10, 2011

News Conference News

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

November 10, 2011

News Industry News

Clinical trial of a new dual therapy stent establishes non-inferiority compared to paclitaxel-eluting stent

November 10, 2011

News Industry News

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

November 10, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Industry News

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

November 09, 2011

News Industry News

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

November 08, 2011

News Industry News

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

November 08, 2011

News Conference News

Preclinical Results Promising for Combo Stent

November 08, 2011

News Industry News

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

November 08, 2011

News Industry News

OrbusNeich’s Genous Stent Demonstrates Most Rapid Coronary Vessel Healing Compared to Bare Metal and Drug Eluting Stents at 14 Days Post-Implantation

November 08, 2011

Advertisement

Repositionable Valve Yields Promising 2-Year TAVR Results

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

Boston Scientific Receives FDA Approval for PROMUS Element™ Plus Platinum Chromium Stent System

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

PRISM Individualized Informed Consent Improves PCI Choice, Experience

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

Two New SES Show Improvement Over First-Generation Stents

Paclitaxel-coated balloon angioplasty demonstrates superior results

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

Clinical trial of a new dual therapy stent establishes non-inferiority compared to paclitaxel-eluting stent

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

Preclinical Results Promising for Combo Stent

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

OrbusNeich’s Genous Stent Demonstrates Most Rapid Coronary Vessel Healing Compared to Bare Metal and Drug Eluting Stents at 14 Days Post-Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content